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Cytokines are key players in numerous inflammatory processes. Demonstration of a heritable component in the variation of
cytokine production would indicate that simultaneous occurrence of conditions might be caused by a heritable inflammatory
characteristic. We applied an extended twin study approach to assess heritability estimates of interleukin (IL)-1b, IL-1ra, IL-10,
IL-6, and TNF-a production capacity after ex vivo stimulation with lipopolysaccharide. Cytokine production capacity was
assessed in 42 monozygotic pairs, 52 dizygotic pairs, one trizygotic triplet, 33 single twins, and 83 additional siblings.
Heritability estimates were derived from variance decomposition models using maximum likelihood estimation. For all
cytokines, over 50% of the variance was genetically determined. IL-1ra and TNF-a had the lowest heritability estimate of 53%.
Estimates for IL-6 and IL-10 were 57 and 62%, respectively. IL-1b had the highest estimate of 86%. We conclude that the
production of cytokines is under tight genetic control.
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Numerous diseases are associated with an increased risk
for other comorbid conditions. For example, patients
with systemic lupus erythematosus have an increased
risk of developing atherosclerotic disease,1 prevalence of
diabetes in patients with multiple sclerosis is three-five-
fold increased compared to the general population,2 and
patients with cancer have an increased risk for develop-
ing neurological degenerations.3 For all these diseases,
inflammatory mechanisms have been implicated.4–9 In
addition, inflammation has also been postulated as
explanation for the simultaneous occurrence of these
conditions.
Cytokines are key players in numerous inflammatory
processes. Upon recognizing an intrinsic or extrinsic
danger signal, innate immune cells start to produce a
variety of cytokines. The pattern of cytokine production
is determined by the pathogen structure and the binding
receptor through which signaling and activation of gene
transcription takes place. Typically, activation of the
innate immune system is not pathogen-specific, but
depends on the binding of evolutionary conserved
pathogen-associated molecular patterns.10,11 Lipopoly-
saccharide (LPS) is one of such an evolutionary con-
served pattern. After LPS activation through Toll-like
receptor (TLR-) 4, innate immune cells immediately
produce a variety of inflammatory mediators such as
interleukin (IL-)1b, IL-1 receptor antagonist (ra), IL-6,
IL-10, and tumor necrosis factor (TNF-) a.12
Although the genes coding for the various cytokines
have been identified, association studies between pro-
duction capacity of cytokines and polymorphisms in or
around the various cytokine genes have given disap-
pointing results.13 This suggests that regulation of
cytokine production might be influenced by other genes,
for example, a regulatory single-nucleotide polymorph-
ism (rSNP).14,15 The unknown regulatory genes may be
localized with linkage analysis, but, to our knowledge,
linkage studies of cytokine production capacity have not
been reported. Even the heritability of variation in
cytokine production is largely unknown.
Identification and quantification of a heritable compo-
nent in the variation of cytokine production would be the
first line of evidence demonstrating that common
disorders such as atherosclerosis, cancer, diabetes, and
multiple sclerosis might share a heritable inflammatory
characteristic. We applied an extended twin study
approach to assess heritability estimates of IL-1b,
IL-1ra, IL-10, IL-6, and TNF-a production capacity after
ex vivo stimulation with LPS.
Characteristics of the 302 subjects included in the
study are given in Table 1. The mean production capacity
of IL-1b, IL-1ra, IL-6, IL-10, and TNF-a was not
statistically different between zygosity groups or be-
tween twins and singleton siblings.
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Using Structural Equation Modeling as implemented
in Mx, in which effects of age and sex can be estimated
while taking into account the dependency of the data (ie
the family structure), we found that production of IL-10
and TNF-a declined significantly with increasing age
(8.9 pg/ml (P¼ 0.04) and 52.0 pg/ml (P¼ 0.03) per
increasing year of age, respectively). Men had signifi-
cantly higher production capacity for IL-1b (1519 pg/ml,
Po0.01), IL-6 (8295 pg/ml, P¼ 0.01), and TNF-a
(1162 pg/ml, Po0.01).
Figure 1 shows scatterplots of cytokine production
capacity of all possible pairs of family members for
monozygotic twin pairs and for dizygotic twin and
sibling pairs as a function of age and sex. Monozygotic
twins have less variation within pairs as compared to
dizygotic twins and sibling pairs. Table 2 indeed shows
that the correlation coefficients for all cytokines are
higher for monozygotic twin pairs than for dizygotic
twin and sibling pairs. This suggests that heritability
plays a role in the LPS-induced cytokine response.
Results from the variance decomposition models con-
firmed that for all cytokines, over 50% of the variance is
genetically determined (Table 2). IL-1ra and TNF-a had
the lowest estimate (53%), while IL-1b had the highest
estimate (86%). The remaining variation in LPS-induced
cytokine response was attributable to nonshared envir-
onmental variance. Common environmental variance
did not significantly contribute to the observed variance
in any of the LPS-induced cytokine responses.
Until now, only two smaller studies had assessed
heritability estimates for TNF-a20 and IL-10.20,21 We now
demonstrate that between-subjects variability in produc-
tion levels of the five cytokines has a genetic background
of more than 50%. For these cytokines, functional
polymorphisms have been described. However, most of
these polymorphisms only explain a small part of the
total variation in cytokine production.13 Recently, both
Tokuhiro et al14 and Helms et al15 demonstrated that a
distant rSNP is important in affecting a DNA site known
to be associated with the autoimmune diseases psoriasis
and rheumatoid arthritis. We hypothesize that a similar
mechanism might play a role in the regulation of the
innate immune response. Since innate cytokine gene
transcription depends on innate signaling pathways
activated by binding pathogen patterns and recognizing
receptor-complexes, this may involve a single or multiple
rSNPs of genes encoding proteins of this signaling
cascade.
We found the strongest heritability estimates for LPS-
induced IL-1b. IL-1b is a highly inflammatory cytokine
for which the margin between clinical benefit and
immunopathology is very narrow in humans.22 Hence,
tight regulation of the production of this cytokine is
essential. Moreover, Toll-like receptors and IL-1 receptors
belong to a broader family of receptors sharing a
conserved cytosolic region termed the Toll-IL-1 receptor
(TIR) domain.23 The high heritability of especially LPS-
induced IL-1b suggests that components of the intracel-
lular signaling mechanisms shared by TIRs explain the
tight genetic control of the innate cytokine response.24
Our findings are in line with the notion that patients
with certain diseases have increased risk for other
comorbid conditions. For example, Marrosu et al2 re-
ported that in families with genetic inheritance of
multiple sclerosis, type I diabetes is three to five times
more prevalent than in families without a history of
multiple sclerosis. We noted that this observed associa-
tion might have an immunogenetic explanation,25 since it
is known that IL-10 production plays a crucial role in
both multiple sclerosis and diabetes.
We deliberately randomly distributed twins and sib-
lings over the various ELISA plates. In this way, variation
between ELISA plates was equally distributed over the
monozygotic and dizygotic twins. Moreover, the mean
cytokine production capacity was equal for twins and
singletons. This finding indicates that twins do not have
an unusual cytokine production pattern which could have
been responsible for our high heritability estimates.
We do not know whether LPS is the right stimulus to
estimate innate immunity. However, cytokine production
Table 1 Characteristics of study participants
Monozygotic twins* (n¼ 90) Dizygotic twins** (n¼ 128) Siblings# (n¼ 84)
No. of females (%) 39 (43%) 80 (63%) 44 (52%)
Mean age (years (s.d.)) 40.1 (13.3) 37.4 (11.9) 39.2 (12.1)
Mean cytokine production (pg/ml (s.d.))
Interleukin-1b (n¼ 299) 6215 (2819) 6361 (3017) 6180 (3268)
Interleukin-1ra (n¼ 302) 33 876 (9734) 33 324 (9479) 35 045 (10239)
Interleukin-6 (n¼ 300) 71 839 (24843) 75 198 (26487) 75 944 (30280)
Interleukin-10 (n¼ 302) 2266 (703) 2225 (849) 2343 (731)
Tumor necrosis factor-a (n¼ 301) 7422 (2863) 8327 (3986) 7284 (3683)
All 302 participants were recruited from a larger study on the genetics of adult brain function.16 The monozygotic twins includes six single
twins and 42 twin pairs, the dizygotic twins include 24 single twins and 52 twin pairs. The siblings include the third subject from one
trizygotic triplet. Cytokine production capacity was assessed with an ex vivo whole blood assay.17 Blood samples were drawn in the morning
before 1100 hours to minimize circadian variation. Heparinized whole blood was diluted five-fold with RPMI-1640, stimulated with 10 ng/ml
LPS, and then incubated for 24 h at 371C and 5% CO2. After centrifugation, the supernatants were stored at 801C until assaying for the
various cytokines using standard ELISA techniques according to the manufacturer’s guidelines (Central Laboratory of the Blood Transfusion
Service, Amsterdam, The Netherlands). Supernatants of subjects were randomly distributed over ELISA plates in order to spread laboratory
variation equally between monozygotic and dizygotic twins.
*Includes 6 single twins and 42 twin pairs.
**Includes 24 single twins and 52 twin pairs.
#Includes the third subject from the trizygotic triplet.
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is not pathogen specific and now it appears to be a
heritable characteristic. Moreover, we have previously
shown that the assay as performed here strongly
associates with outcomes of and susceptibility for
various inflammatory diseases at young and old age,
even though these diseases are not LPS mediated.7,20,26–28
In conclusion, our data provide strong evidence for a
genetic basis for numerous inflammatory mediated
diseases. Future linkage analyses in this extended twin
panel using this intermediate phenotype will be set up to
identify genomic regions important for LPS-induced
cytokine production capacity. This will be followed by
Figure 1 Scatterplots of cytokine production capacity of all
nonindependent related pairs of family members, ordered across
zygosity (monozygotic twins vs dizygotic twins or siblings). LPS-
induced production capacity of IL-1b, IL-1ra, IL-6, IL-10, and TNF-
a. Monozygotic twins are plotted in the left column, dizygotic twins
and siblings are plotted in the right column. Squares are males, dots
are females, open symbols are pairs under the median age of 35
years, solid symbols are pairs above the median age of 35 years.
Dizygotic twins with siblings were included in the plots if the
difference in age was less than 5 years. Opposite sex pairs were
excluded from the plots.
Table 2 Correlation coefficients and heritability estimates for the
various cytokines
Cytokine Monozygotic
twins
Dizygotic twins
and siblings
Heritability
(95% CI)
Interleukin-1b 0.86 0.32 0.86 (0.76–0.92)
Interleukin-1ra 0.58 0.20 0.53 (0.32–0.70)
Interleukin-6 0.59 0.25 0.57 (0.36–0.73)
Interleukin-10 0.67 0.24 0.62 (0.41–0.76)
Tumor necrosis
factor-a
0.55 0.25 0.53 (0.30–0.70)
Correlations were corrected for age and sex where found
statistically significant (IL-10 and TNF-a were corrected for age,
interleukin-1b, interleukin-6, and TNF-a were corrected for sex).
Heritability analysis proceeded in several stages. First, the
distribution of each cytokine was visually inspected for outliers,
which were subsequently eliminated from the analyses (three
outliers for IL-1b, two for IL-6, and one for TNF-a). Then, for each
cytokine, a saturated statistical model was built, consisting of 11
estimated parameters: three grand means (mean cytokine levels of
monozygotic twins, dizygotic twins, and siblings), two covariates
(age, sex), three variances (for monozygotic twins, dizygotic twins,
and siblings), and three covariances (for monozygotic twin pairs,
dizygotic twin pairs, and siblings). Next, the full model was
reduced to a restricted model, the variance decomposition model,
which included only parameters that contributed significantly to
the model. All analyses were carried out using the software package
Mx.18 The observed interindividual variation in cytokine production
was decomposed into additive genetic variation [A], common
environmental variation shared by family members [C], and
nonshared environmental variation [E].19 By definition, common
environmental variation [C] includes all environmental sources of
variation that twins and siblings from the same family share, while
nonshared environmental variation [E] is the environmental
variation that is unique for an individual which is typically not
shared with other family members. For monozygous twin pairs,
similarities of additive genetic [A] and shared environmental
influences [C] were fixed at 100%. For dizygotic twin pairs and
nontwin sib pairs, similarity of additive genetic influences [A] was
fixed at 50%. If the saturated models indicated no difference in
covariation between dizygotic twin pairs and sib pairs, similarity in
common environmental influences [C] was fixed at 100%. Similarity
in nonshared environmental influences [E] was fixed at 0% for all
family members. This component also includes measurement error.
The total variance is A+C+E. The expectation for the covariance
between monozygotic twins is A+C, and the expectation for the
dizygotic twins and sib pairs is 12Aþ C. Heritability (h2) is calculated
as the proportional contribution of genetic variation to the total
observed variation: A/(A+C+E).
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fine mapping and association analyses within those
regions. By the identification of the actual allelic variants
influencing cytokine production, we will further our
understanding of the underlying genetic mechanism of
inflammatory mediated diseases.
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